참고문헌
- Howlander N NA, Krapcho M, Garshell J, Millder D, Altekruse SF, Kosary CL, et al. SEER Cancer Statistics Review. National Cancer Institute; Bethesda, MD: 1975-2011. 2014.
- Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306. https://doi.org/10.1056/NEJM199801293380506
- Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 2000;11:1083-1089. https://doi.org/10.1023/A:1008322002520
- Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13:453-464. https://doi.org/10.1245/ASO.2006.05.042
- Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2012;97:E898-906. https://doi.org/10.1210/jc.2011-3269
- Kasaian K, Wiseman SM, Walker BA, Schein JE, Zhao Y, Hirst M, et al. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy. BMC Cancer. 2015;15:984. https://doi.org/10.1186/s12885-015-1955-9
- Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016;42:47-55. https://doi.org/10.1016/j.ctrv.2015.11.003
- Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22:1104-1139. https://doi.org/10.1089/thy.2012.0302
- Glaser SM, Mandish SF, Gill BS, Balasubramani GK, Clump DA, Beriwal S. Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival. Head Neck. 2016;38 Suppl 1:E2083-2090. https://doi.org/10.1002/hed.24384
- Lowe NM, Loughran S, Slevin NJ, Yap BK. Anaplastic thyroid cancer: The addition of systemic chemotherapy to radiotherapy led to an observed improvement in survival--a single centre experience and review of the literature. ScientificWorldJournal. 2014;2014:674583.
- Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: A review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007;6:609-621. https://doi.org/10.1517/14740338.6.5.609
- Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, Miya A, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010;20:7-14. https://doi.org/10.1089/thy.2009.0115
- Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-630. https://doi.org/10.1056/NEJMoa1406470
- Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDAMB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14:5459-5465. https://doi.org/10.1158/1078-0432.CCR-07-5270
- Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol. 2013;5:345-352. https://doi.org/10.4254/wjh.v5.i7.345
- Adjibade P, St-Sauveur VG, Quevillon Huberdeau M, Fournier MJ, Savard A, Coudert L, et al. Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells. Oncotarget. 2015;6:43927-43943. https://doi.org/10.18632/oncotarget.5980
- Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013;23:600-604. https://doi.org/10.1089/thy.2012.0103
- Denaro N, Nigro CL, Russi EG, Merlano MC. The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther. 2013;9:1231-1241.
- Catalano MG, Pugliese M, Gallo M, Brignardello E, Milla P, Orlandi F, et al. Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial. Int J Endocrinol. 2016;2016:2930414.
- Park KC, Kim SM, Jeon JY, Kim BW, Kim HK, Chang HJ, et al. Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer. Neoplasia. 2017;19:145-153. https://doi.org/10.1016/j.neo.2016.12.005
- Inoue H, Hwang SH, Wecksler AT, Hammock BD, Weiss RH. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther. 2011;12:827-836. https://doi.org/10.4161/cbt.12.9.17680
- Jing C, Gao Z, Wang R, Yang Z, Shi B, Hou P. Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 2017;7:903-912.
- Merz M, Komljenovic D, Zwick S, Semmler W, Bauerle T. Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti- tumour and anti-resorptive effects in experimental breast cancer bone metastases. Eur J Cancer. 2011;47:277-286. https://doi.org/10.1016/j.ejca.2010.08.019
- Kuo TC, Lu HP, Chao CC. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem Pharmacol. 2011;82:184-194. https://doi.org/10.1016/j.bcp.2011.04.008
- Niero A, Emiliani E, Monti G, Pironi F, Turci L, Valenti AM, et al. Paclitaxel and radiotherapy: Sequence-dependent efficacy--a preclinical model. Clin Cancer Res. 1999;5:2213-2222.
- Hiro J, Inoue Y, Toiyama Y, Yoshiyama S, Tanaka K, Mohri Y, et al. Possibility of paclitaxel as an alternative radiosensitizer to 5-fluorouracil for colon cancer. Oncol Rep. 2010;24:1029-1034.
- Kurdoglu B, Cheong N, Guan J, Corn BW, Curran WJ, Jr., Iliakis G. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines. Clin Cancer Res. 1999;5:2580-2587.
- Zhang H, Hyrien O, Pandya KJ, Keng PC, Chen Y. Tumor response kinetics after schedule-dependent paclitaxel chemoradiation treatment for inoperable non-small cell lung cancer: A model for low-dose chemotherapy radiosensitization. J Thorac Oncol. 2008;3:563-568. https://doi.org/10.1097/JTO.0b013e3181729dbe
- Schlumberger M, Tahara M. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N Engl J Med 2015;372:621-630 https://doi.org/10.1056/NEJMoa1406470
- Tahara M, Brose MS. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019;106:61-68. https://doi.org/10.1016/j.ejca.2018.10.002